Clinical Trial Update: A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities [Phase 2]

View source ↗

Summary

A Phase 2 clinical study evaluating a VRd-based regimen combined with CART-ASCT-CART2 in newly diagnosed multiple myeloma patients with p53 abnormalities; curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• CAR-T cell therapy CART-ASCT-CART2 (CAR-T cell therapy)
• DEXAMETHASONE (Dexamethasone)
• Lenalidomide (lenalidomide)
• VRd-based regimen (bortezomib/lenalidomide/dexamethasone)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Multiple Myeloma | Phase 2 | Status: RECRUITING